Corangin

Nazione: Nuova Zelanda

Lingua: inglese

Fonte: Medsafe (Medicines Safety Authority)

Principio attivo:

Isosorbide mononitrate 40mg;  

Commercializzato da:

Novartis New Zealand Ltd

INN (Nome Internazionale):

Isosorbide mononitrate 40 mg

Dosaggio:

40 mg

Forma farmaceutica:

Modified release tablet

Composizione:

Active: Isosorbide mononitrate 40mg   Excipient: Colloidal silicon dioxide Hydrated silica Hypromellose Lactose monohydrate Macrogol 4000 Magnesium stearate Polyvidone 30

Confezione:

Blister pack, 30 tablets

Classe:

Prescription

Tipo di ricetta:

Prescription

Prodotto da:

Cambrex Karlskoga AB

Indicazioni terapeutiche:

Corangin is indicated for: · Prevention of angina pectoris attacks, and also in cases where symptoms of angina pectoris persist after myocardial infarction. Corangin may be used either as monotherapy or in combination with other antianginal agents (e.g. beta-blockers or calcium antagonists).

Dettagli prodotto:

Package - Contents - Shelf Life: Blister pack, - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Data dell'autorizzazione:

1989-07-20

Foglio illustrativo

__________________________________________________________________________________________________ 
Corangin
®                                             

                    1 

CORANGIN
® 
_40mg tablet _
_isosorbide-5-mononitrate_ 
_____________________________________________________________________________________ 
CONSUMER MEDICINE INFORMATION 
____________________
WHAT IS IN THIS LEAFLET 
__________________________________ 

This leaflet answers some common 
questions about Corangin.  

It does not contain all the available 
information. It does not take the 
place of talking to your doctor or 
pharmacist. 

All medicines have risks and 
benefits. Your doctor has weighed 
the risks of you having   
Corangin against the benefits they 
expect it will provide. 

IF YOU HAVE ANY CONCERNS ABOUT 
THIS MEDICINE, ASK YOUR DOCTOR OR 
PHARMACIST. 

KEEP THIS LEAFLET. 
You may need to read it again. 
________________________
WHAT CORANGIN IS 
USED FOR 
________________________

Corangin contains the active 
ingredient isosorbide-5-
mononitrate.  It belongs to a class of 
medicines know as organic nitrate 
vasodilators, meaning that they 
cause blood vessels to widen.  
Widening the blood vessels means 
that blood flow and blood pressure 
is improved, and so the heart does 
not need to do as much work and 
does not need as much oxygen. 

Corangin is used to prevent angina 
pectoris and to treat heart failure.  It 
is not suitable for the treatment of 
acute attacks of angina pectoris. 
ASK YOUR DOCTOR IF YOU HAVE ANY 
QUESTIONS ABOUT WHY THIS 
MEDICINE HAS BEEN PRESCRIBED FOR 
YOU. 
Your doctor may have prescribed it 
for another purpose.  

Corangin is only available with a 
doctor's prescription. It is not 
add

Scheda tecnica

NEW ZEALAND DATA SHEET 

CORANGIN
®  
ISOSORBIDE-5-MONONITRATE 
TRADE NAME 
CORANGIN
® 
40 mg and 60 mg slow release divisible tablets 
DESCRIPTION AND COMPOSITION 
PHARMACEUTICAL FORMS 
Slow-release tablets , divisible (Divitabs
®
), containing 40 or 60 mg isosorbide-5-mononitrate. 
ACTIVE SUBSTANCE 
Isosorbide-5-mononitrate. One tablet contains 40 mg or 60 mg. 
ACTIVE MOIETY 
Isosorbide-5-mononitrate. 
EXCIPIENTS 
Tablets (40 mg, 60 mg): silicagel, aerosil 200, lactose, magnesium
stearate, Methocel 
K 100 M premium (hydroxypropyl-methylcellulose), polyethylenglycol
4000, 
polyvinylpyrrolidon K 30. 
INDICATIONS 
Corangin is indicated for: 
•  Long term treatment of ischemic heart disease, 
•  Prevention of angina pectoris attacks, and also in cases
where symptoms of angina pectoris 
persist after myocardial infarction. Corangin may be used either as
monotherapy or in 
combination with other antianginal agents (e.g. beta-blockers
or calcium antagonists). 
•  Treatment for chronic heart failure, in combination with
digitalis or other positive-inotropic 
agents and/or diuretics. 
DOSAGE AND ADMINISTRATION 
GENERAL RULES 
Corangin is not intended for the immediate relief of acute attacks
of angina pectoris; if they 
occur, the additional use of rapid-acting nitrate preparations is
indicated. 

Development of tolerance or attenuation of effect may occur with all
long-acting nitrates in 
individual patients on continuous treatment. This can be reversed
with low-nitrate blood 
levels (as observed with Corangin at the end of the dosing
interval). 
ANGINA PECTORIS 
The starting dose should be 1 tablet of Corangin 40 mg once
daily and increased as required, 
either by adding one-half of a 40 mg tablet or changing to the 60
mg tablet. Depending on the 
time of day at which the angina pectoris attacks occur in the
individual patient, the slow-
release tablet can be taken either in the morning or in the
evening. 
If treatment with Coran